פעילות רפואית
"Bortezomib Teva is indicated for the treatment of patients with multiple myeloma.
Bortezomib Teva is indicated for the treatment of patients with mantle cell lymphoma who have
received at least one prior therapy.
Bortezomib Teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone
is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma
who are unsuitable for haematopoietic stem cell transplantation"